Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $917.7 million.

  • Dexcom's Cash & Equivalents rose 5141.07% to $917.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $917.7 million, marking a year-over-year increase of 5141.07%. This contributed to the annual value of $917.7 million for FY2025, which is 5141.07% up from last year.
  • Latest data reveals that Dexcom reported Cash & Equivalents of $917.7 million as of Q4 2025, which was up 5141.07% from $1.8 billion recorded in Q3 2025.
  • Dexcom's 5-year Cash & Equivalents high stood at $1.8 billion for Q3 2025, and its period low was $566.3 million during Q4 2023.
  • Its 5-year average for Cash & Equivalents is $902.2 million, with a median of $793.3 million in 2022.
  • As far as peak fluctuations go, Dexcom's Cash & Equivalents tumbled by 5166.52% in 2022, and later soared by 19550.87% in 2025.
  • Dexcom's Cash & Equivalents (Quarter) stood at $1.1 billion in 2021, then crashed by 38.98% to $642.3 million in 2022, then decreased by 11.83% to $566.3 million in 2023, then increased by 7.03% to $606.1 million in 2024, then soared by 51.41% to $917.7 million in 2025.
  • Its Cash & Equivalents was $917.7 million in Q4 2025, compared to $1.8 billion in Q3 2025 and $1.2 billion in Q2 2025.